Tracery is a clinical stage ophthalmic imaging & image analysis company specializing in Precision Medicine and Customized Clinical Trial design, currently focused on Age Related Macular Degeneration (AMD).
For diseases of the eye, biopsy is not possible, so there is a reliance on imaging technology, which poses a significant challenge of drug development, and requires the incorporation of imaging biomarkers (IB).
Dry AMD is a complex disease of innate immunity, oxidative stress and lipid dysregulation that relies on IBs. Unfortunately, the only measure as a clinical trial endpoint is the standard Fundus Autofluorescence (FAF) which can only measure tissue after it is lost, limiting prevention studies.
Our Technologies
Integrates a Novel Imaging Modality, DNIRA, into Standard of Care Modalities
